Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Stimulating mir-106b expression to regenerate the myocardium

Objectif

Most people who develop ischemic HF have (or had) an ischemic heart condition first (e.g. myocardial infarction, MI). Restoring damaged heart muscle tissue therefore represents a fundamental mechanistic strategy to treat HF. Cardiac regeneration after ischemic damage can be achieved by stimulating the proliferation of already existing (endogenous) cardiomyocytes rather than having to rely on the implantation of exogenous cells (i.e. stem cell therapy). Compelling evidence supports that expanding the endogenous cardiomyocyte proliferation capacity by gene therapy appears to represent a promising approach to achieve endogenous cardiac regeneration. Species of non-coding RNA molecules, microRNAs, have been demonstrated to stimulate cardiomyocyte proliferation and the recognition of microRNAs as potential regenerative targets marks a major step towards fundamentally new therapeutic concepts that SUMMA addresses in ischemic heart disease. In the context of the ERC-Starting Grant project CALMIRS, we identified the miR-106b~25 cluster with high potential as new target for therapy to stimulate regeneration of the heart by promoting cardiomyocyte proliferation. Within SUMMA, we aim to advance these valuable research results on microRNA cardiac gene therapy in mice towards commercial proof-of-concept. During this project, proof-of-concept efficacy studies in a large animal (e.g. porcine) model of cardiac ischemia will be performed, while simultaneously market research, IP strategy development and business development activities take place to maximize the value of the project’s results. Different business models will be studied in terms of market research, IP strategy and business development to eventually consolidate a commercial strategy and business case for presenting our business proposition to strategic partners or venture capitalists.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

ERC-POC - Proof of Concept Grant

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2017-PoC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

UNIVERSITEIT MAASTRICHT
Contribution nette de l'UE
€ 149 875,00
Adresse
MINDERBROEDERSBERG 4
6200 MD Maastricht
Pays-Bas
Région
Zuid-Nederland Limburg (NL) Zuid-Limburg
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 149 875,00

Bénéficiaires (1)